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Abstract We report here a novel human gene, hMRS3/4,
encoding a putative mitochondrial transporter structurally and
functionally homologous to the yeast mitochondrial RNA
splicing proteins 3 and 4. These proteins belong to the family
of mitochondrial carrier proteins (MCF) and are likely to
function as solute carriers. hMRS3/4 spans V10 kb of genomic
DNA on chromosome 10q24 and consists of four exons that
encode a 364-aa protein with six transmembrane domains. A
putative splice variant, encoding a 177-aa protein with three
transmembrane domains, was also identified. hMRS3/4 has a
well-conserved signature sequence of MCF and is targeted into
the mitochondria. When expressed in yeast, hMRS3/4 efficiently
restores the mitochondrial functions in mrs3omrs4o knock-out
mutants. Ubiquitous expression in human tissues and a well-
conserved structure and function suggest an important role for
hMRS3/4 in human cells. ß 2001 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
The mitochondrial proteins MRS3 and MRS4 (yMRS3 and
yMRS4) were ¢rst identi¢ed in Saccharomyces cerevisiae in
1991 by their ability to suppress defects in the maturation
of mitochondrial group II intron-containing transcripts [1].
Subsequently, they were found to be integral membrane pro-
teins in the inner mitochondrial membrane, belonging to the
superfamily of mitochondrial carriers (MCF), and having
structural features of solute carriers [2]. This superfamily in-
cludes the adenine nucleotide translocator, the phosphate car-
rier, several mitochondrial metabolite carriers, as well as other
proteins of shared structure and unknown function ([3] ; Pro-
tein family database, Pfam; Prosite accession number
PDOC00189).
We have undertaken positional cloning projects to charac-
terize the genes underlying autosomal dominant progressive
external ophthalmoplegia with multiple mtDNA deletions
(adPEO) and infantile-onset spinocerebellar ataxia (IOSCA).
The genes of one form of adPEO and IOSCA have been
mapped to chromosome 10q24 between DNA markers
D10S198 and D10S1795 [4,5], and D10S192 and D10S1265
[6,7], respectively. Expressed sequence tags (ESTs) weakly ho-
mologous to the yMRS3 and yMRS4 had previously been
mapped in the immediate vicinity of this region.
Here we present the cloning and characterization of a novel
human gene, hMRS3/4, encoding a putative mitochondrial
transporter with signi¢cant structural homology to the closely
related yMRS3 and yMRS4, and with ability to replace its
homologs in yeast. Sequence analyses were carried out to
clarify the possible involvement of hMRS3/4 in adPEO and
IOSCA diseases, sharing the genomic locus with this trans-
porter.
2. Materials and methods
2.1. Construction of the hMRS3/4 cDNA sequence
To construct the hMRS3/4 cDNA sequence, 104 ESTs homologous
with yMRS3 and yMRS4, and some of them previously localized to
10q24, were identi¢ed from GenBank. The putative hMRS3/4 cDNA
was constructed by aligning the overlapping ESTs (GenBank ac-
cession numbers AA234450, AA361317, AA234031, AA449277,
AA298599 and AA298105) and cDNA sequences of corresponding
IMAGE cDNA clone inserts (clone numbers 77169, 346560, and
1192817; 3P cDNA representing exons 2^4). In addition, cDNA se-
quence information was gained by exon predictions and homology
comparisons between yMRS4 and the available genomic sequence
of hMRS3/4 locus (GenBank accession number AC007643). The
ESTs represented two di¡erent splice forms, and the cDNAs con-
structed from these had 177-aa and 364-aa open reading frames
(ORF). The two forms shared the 3P UTR and exon 4, but had di¡er-
ential splicing of exons 2 and 3 (Fig. 1). About 13% of the ESTs
corresponded to the 177-aa form. The rest were either homologous
with the 364-aa form or too short to extend to the variable sequence.
The constructed hMRS3/4 cDNAs and the correct genomic sequence
were con¢rmed by polymerase chain reaction (PCR) ampli¢cation of
reverse-transcribed muscle, brain or lymphoblast RNA, of genomic
DNA, and by subsequent sequencing. Table 1 shows the PCR primers
used. PCR ampli¢cations were carried out with either Dynazyme II
DNA polymerase (Finnzymes, Finland) or the High Fidelity PCR
Master kit (Boehringer-Mannheim-Roche) according to the instruc-
tions of the manufacturers and with primer-speci¢c annealing temper-
atures. BigDye Terminator cycle sequencing protocol (Perkin Elmer)
was used for sequencing reactions, and subsequent sequence analyses
of both DNA strands were carried out on ABI377 sequencer (Perkin
Elmer).
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2.2. Genomic structure of the hMRS3/4 gene
The exact genomic structure of hMRS3/4 was determined by com-
parison of the cDNA sequence to the genomic sequence obtained by
DNA sequencing or by searching public databases. Recently, the en-
tire genomic sequence of the hMRS3/4 locus became available in
GenBank (accession number AC007643).
2.3. Computer analyses
All sequences were aligned using Sequencher 3.0 software (Gene
Codes Corporation, Ann Arbor, MI, USA) or GeneJockey II (Bio-
soft, Cambridge, UK). Nucleotide and protein sequence searches were
carried out with BLAST algorithms against public databases. Exon
predictions from genomic sequence were carried out using programs
EbEST, Genexpress, GeneJockey II, and Genscan. Programs ORF
Finder and eukaryotic ORF ID at BCM Search Launcher were
used in predicting ORFs from the cDNA sequence. Programs Predict-
Protein, Pro¢leScan, ProDom, PSORT II, ScanProsite, and TMpred
were used in predicting the potential features of hMRS3/4. (http://
web.wi.mit.edu/bio/pub/biopage2.html/).
2.4. Re¢ned chromosomal assignment of hMRS3/4 gene
The presence of hMRS3/4 sequence in a panel of 83 radiation hy-
brids (RH, Radiation Hybrid Panel G3, RH01.05, Research Genetics,
Huntsville, AL, USA) and in a YAC contig on the 10q24, constructed
from the publicly available mega-YACs (CEPH), was analyzed by
PCR ampli¢cation using primers MRS4-5+MRS4-8 and 7875F+
8284R (Table 1). The PCR products were visualized by 1% agarose
gel electrophoresis.
2.5. Sequence analyses in patient and control subjects
The 3.2-kb genomic sequence of the 3P-end of hMRS3/4 was am-
pli¢ed in three overlapping fragments (primer pairs 8284R+10636F,
10634R+1805F2, and 10637R+1805F2; Table 1), and the ¢rst exon in
a single fragment (primers MRS4ex1F+R; Table 1), from the DNA
samples of two adPEO patients, originating from both a Finnish and
a Pakistani adPEO family both linked to chromosome 10q24 [4,5],
one IOSCA patient from a family also linked to 10q24 [6,7], and two
control subjects. Both DNA strands of the PCR fragments were se-
quenced with PCR and internal primers by ABI377 BigDye Termina-
tor cycle sequencing protocol according to manufacturer’s instruc-
tions. To enhance detection of a heterozygous mutation, most of
the PCR fragments were additionally analyzed by single-strand con-
formation polymorphism (SSCP) analysis as previously described [8].
2.6. Northern blot analysis
To analyze the expression pattern of hMRS3/4, the 1.1-kb insert of
IMAGE clone 1192817, PCR-ampli¢ed with vector primers and pu-
ri¢ed with Qiaquick PCR preps (Qiagen, Valencia, CA, USA) accord-
ing to the instructions of the manufacturer, and the 1.1-kb RT-PCR
product ampli¢ed with primers MRS4-20+21 from lymphoblast RNA
template, were radioactively labeled by standard random-prime meth-
odology (Fig. 1). Additionally, to detect speci¢cally the 364-aa splice
form, a 347-bp RT-PCR product ampli¢ed with MRS4-34+39 was
labeled by integrating 32P during PCR. These probes were hybridized
separately to human multiple tissue Northern (MTN1) blot contain-
ing mRNAs from heart, brain, placenta, lung, liver, skeletal muscle,
kidney and pancreas. The 1192817 insert was also hybridized to hu-
man brain MTN-blot II containing mRNAs from eight di¡erent re-
gions of the brain (Clontech, Palo Alto, CA, USA). Northern hybrid-
izations were carried out in ExpressHyb solution (Clontech, Palo
Alto, CA, USA) in accordance with the instructions of the manufac-
turer. After hybridizations, the membranes were exposed to X-ray ¢lm
at 370‡C overnight or for several days.
2.7. Mitochondrial targeting of hMRS3/4
The hMRS3/4 cDNA encoding the 364-aa splice form, lacking only
the non-conserved 5P-end, and the cDNA encoding the 177-aa variant,
were ampli¢ed by high-¢delity PCR with primers MRS4-41+21 and
MRS4-20 and -21, respectively (Table 1), and cloned into pCR2.1
(Invitrogen, San Diego, CA, USA). They were reampli¢ed with
MRS4-207 and -201, MRS4-200 and MRS4-201 to introduce an
EcoRV and a HindIII site to facilitate cloning and to eliminate the
stop codon. The product was subcloned into pB.RSV.PDX-1VGFP
[9], fusing the hMRS3/4 and EGFP (enhanced green £uorescence
protein) cDNAs in-frame and creating pRSV.hMRS3/4-177VEGFP
and pRSV.hMRS3/4-364VEGFP. The constructs were con¢rmed by
DNA sequence analysis. HEK293 cells were grown on 24-mm glass
coverslips in Dulbecco’s modi¢ed Eagle medium (DMEM) containing
4.5 g/l glucose and supplemented (DMEM+) with 100 U/ml penicillin,
100 Wg/ml streptomycin, and 10% fetal calf serum at 5% CO2 and
37‡C. Transfections of pRSVhMRS3/4-177 and -364VEGFP by lipo-
fectamine were performed overnight in DMEM. Cells were studied for
expression of hMRS3/4VEGFP 46^72 h post-transfection by confo-
cal laser scanning microscopy (CLSM) as described previously [10].
Prior to analysis the cells were loaded for 20 min with 250 ng/ml
MitoTracker Red CMXRos (Molecular Probes, Eugene, OR, USA)
in DMEM+ at 37‡C, washed with medium and incubated for further
20 min in DMEM+ at 37‡C. Cells were monitored for EGFP- and
MitoTracker-£uorescence using a Leica CLSM (Leica Lasertechnik,
Heidelberg, Germany). The coverslips were placed in a perifusion
chamber mounted on a Leica Fluovert FU inverted microscope (Leica
Lasertechnik, Heidelberg, Germany), at 37‡C. The following settings
were used: 100U/1.3 oil Leitz Fluotar objective lens, excitation using
a krypton-argon laser (bands 488 and 568 nm), excitation ¢lter
KP590, double-dichroic mirror 488/568, and emission ¢lter HQ525/
50 for EGFP and a long-pass 580-nm ¢lter for MitoTracker Red,
respectively. A beam-splitter at 580 nm was used to separate the
EGFP and MitoTracker Red signals. Presentation images were gen-
erated using Adobe Photoshop version 4.0.
2.8. Transfection of hMRS3/4 into yeast mrs3omrs4o and mrs2o
knock-out mutants
The hMRS3/4 cDNA encoding the 364-aa protein and lacking only
the non-conserved 5P-end (ampli¢ed with primers MRS4-41 and
MRS4-21) was cloned into pCR2.1 (Invitrogen, San Diego, CA,
USA). The insert was further ampli¢ed with hMRS4-SacI and
hMRS4-HindIII (Table 1). The PCR product was digested with re-
striction enzymes SacI and HindIII and cloned into the corresponding
sites of the vector pVT-U [11] creating plasmid pVT-U-hMRS3/4. The
pVT-U-hMRS3/4 plasmid was digested with restriction enzyme SphI
and the fragment containing hMRS3/4 with ADH1 gene promoter and
ADH1 3P untranslated region was cloned into the SphI site of YC-
plac22 and YEplac112 vectors [12] creating plasmids YCp-lac22-
hMRS3/4 and YEplac112-hMRS3/4, respectively. Plasmid pVT-U-
hMRS3/4 was transformed into yeast S. cerevisiae strain
DBY747mrs2-1 v [13] and plasmids YCp-lac22-hMRS3/4 and YE-
plac112-hMRS3/4 were transformed into yeast S. cerevisiae strain
DBY747mrs3omrs4o (GW6/gd34) [2].
3. Results
3.1. Genomic structure and cDNA of hMRS3/4 gene
The hMRS3/4 cDNAs of 1448 bp and 1889 bp were con-
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structed from overlapping EST sequences available in Gen-
Bank, cDNA clone sequences representing these ESTs, and
sequencing of RT-PCR products. Comparing the cDNA se-
quences with the genomic sequence of the locus revealed that
the gene consists of four exons spanning about 10 kb of ge-
nomic DNA (Fig. 1). Exons 2^4 corresponded to the EST and
cDNA clone sequences and consequently also to the tran-
scribed sequences predicted from the genomic sequence with
program EbEST. Also the program Genscan at MIT suc-
ceeded in correctly predicting the internal and terminal exons
of hMRS3/4. The ¢rst exon was predicted with program Gen-
express from genomic sequence AC007643, and its presence
was con¢rmed by RT-PCR. Additionally, three vertebrate
ESTs homologous to yMRS3 and yMRS4 (GenBank acces-
sion BE012485, AW326482 and AA104365) were homologous
to the predicted human exon 1. The ¢rst and the third intron
splicing of hMRS3/4 followed the conventional GT-AG rule,
whereas the second did not. cDNA- and RT-PCR sequences
revealed that the exons 2 and 3 are alternatively spliced with
either (i) the 5P-end of exon 2 (228 bp) and 3P-end of exon 3
(58 bp) in the transcript (1448 bp variant) or (ii) full-length
exons 2 and 3 in the transcript (1889-bp variant; Fig. 1). Both
of these variants are supported by several ESTs from man,
mouse, and cow, and by sequencing of RT-PCR products.
The 1448-bp splice variant encodes a polypeptide of 364 aa
in length. The likely initiator ATG in this cDNA occurs at
nucleotide 30, is followed by an ORF of 1095 bp with a stop
codon at nt 1125, and a polyA-signal at nt 1431. The 1889-bp
splice variant possesses an ORF encoding a 177-aa polypep-
tide, identical to the C-terminus of the 364-aa protein (Figs. 1
and 2). Fig. 1 schematically shows the genomic structure of
hMRS3/4 and the composition of the cDNA splice variants.
Exact nucleotide and amino acid sequences of the splice var-
iants are available in public databases (GenBank accession
numbers AF327402 and AF327403; EMBL accession num-
bers AJ303077 and AJ303078).
3.2. Mapping hMRS3/4
To accurately map hMRS3/4, the G3 radiation hybrid panel
and a YAC contig on 10q24 were analyzed using hMRS3/4-
speci¢c PCR primers. A single product was ampli¢ed with
MRS4-5 and -8 (Table 1) from total human DNA and from
eight samples (no. 1, 44, 51, 57, 60, 64, 79, 82) of the radiation
hybrid DNAs, while no PCR product was obtained in the
other hybrids, mouse or hamster DNA. Combining Chromo-
some 10 RH Map, SHGC Chr.10 Radiation Hybrid Map
(G3) and RH Consortium Gene Map ’98-Chr. 10 (G3 panel;
http://www.gdb.org/) data revealed that hMRS3/4 maps
close to the DNA marker D10S198, which matches well
with the transcript map (http://www.ncbi.nlm.nih.gov/cgi-bin/
SCIENCE96). This was con¢rmed by STS content mapping
with hMRS3/4-speci¢c primers of CEPH-mega-YAC contig
representing the 10q24 region (data not shown).
3.3. Expression pattern of hMRS3/4 in tissues
Northern hybridization analyses utilizing the insert of the
IMAGE cDNA clone 1192817 as a probe identi¢ed a major
hMRS3/4 transcript of approximately 1.8 kb in all tissues
examined (placenta, lung, kidney, pancreas, liver, brain, skel-
etal muscle and heart), with the strongest signals from heart,
skeletal muscle, and liver (Fig. 2). A similar expression pattern
was seen in the hybridization with MRS4-39+34 RT-PCR
product, which was speci¢c to the cDNA of the 364-aa
form (results not shown). In all hybridizations, weak signals
of approximately 3.2 and 4.4 kb were observed in all tissues,
except that the 4.4-kb signal was absent in the brain. These
signals most probably result from non-speci¢c hybridization
or transcripts with a high sequence homology with hMRS3/4.
The 1.8-kb signal corresponds to the length of the cDNA
splice variant encoding the 177-aa partial protein. No signal
corresponding to the 1448-bp cDNA encoding the 364-aa
variant could be detected. However, several other lines of
evidence clearly show that the 1448-bp cDNA encodes the
functional protein variant. The absence of Northern signal
may indicate that we are still lacking some of the 5P untrans-
lated sequence of the 364-aa cDNA, and that the two cDNA
signals overlap with each other in Northerns (Fig. 2).
Fig. 2. Northern blot analysis of hMRS3/4. Hybridization with the
insert of IMAGE cDNA clone 1192817 as a probe revealed highest
expression levels in heart, skeletal muscle, and liver (left : MTN-
blot; middle: brain-MTN-blot). The equal loading of RNA on lanes
was con¢rmed by probing the same membrane with L-actin.
Fig. 1. Genomic organization and cDNA composition of hMRS3/4.
The gene spans V10 kb of genomic DNA and contains four exons
transcribed as (i) a 1448-bp splice variant with an estimated coding
region of 1095 bp, corresponding to a polypeptide of 364 aa and
(ii) a 1889-bp splice variant having an ORF encoding a 177-aa poly-
peptide. EST, cDNA clone and RT-PCR sequences used in con-
structing the full-length cDNAs are shown below each splice var-
iant. The cDNA sequence constitutions of the two di¡erent probes
for Northern analysis are shadowed. Arrows below exons 2 and 3
show alternative splice sites.
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3.4. Mitochondrial targeting of hMRS3/4
To test the subcellular localization of hMRS3/4, its coding
sequence for the 364-aa and the 177-aa protein were tagged
with EGFP. MitoTracker Red CMXRos was used as a mito-
chondrial marker. The signals of MitoTracker and hMRS3/4-
177 and -364VEGFP co-localized in the mitochondria of
transfected HEK293 cells, showing that both proteins are tar-
geted into the mitochondria (Fig. 3).
3.5. hMRS3/4 structure and conservation
BLAST searches with the 364-aa hMRS3/4 as a query se-
quence against SwissProt database showed 38% identity and
55% similarity with the yMRS4 (E = 7e-53), and 37% identity
and 52% similarity with the yMRS3 (E = 1e-52). Programs
ProDom, PredictProtein, Pro¢leScan, and Tmpred suggested
that the 364-aa protein contains six transmembrane helical
domains conserved in MCF proteins between species (Fig.
Fig. 3. Mitochondrial localization of the 177-aa (upper pictures) and 364-aa (lower pictures) hMRS3/4 protein variants. HEK293 cells, trans-
fected with pRSV.hMRS3/4VEGFP, were loaded with MitoTracker Red CMXRos. Fluorescence images were obtained by CLSM as described
in Section 2. The green color is used as the digital pseudocolor for the £uorescence emitted by hMRS3/4-177 or -364VEGFP, red is the digital
pseudocolor for £uorescence emitted by MitoTracker Red, and yellow results from their overlap, indicating the co-localization of hMRS3/
4VEGFP and MitoTracker Red in mitochondria of transfected HEK293 cells.
Fig. 4. Multiple-alignment of hMRS3/4 with other members of MCF. The multiple-alignment was performed with ClustalX and improved with
MacBoxshade. The boxes indicate the conservative transmembrane domains [2]. The sites of the conservative signature sequence are underlined.
MRS: mitochondrial RNA splicing: MRS3/4-1: 177-aa variant; MRS3/4-2: 364-aa variant; BMCP: brain mitochondrial carrier protein; UCP:
brown fat uncoupling protein; MCAT: mitochondrial carnitine/acylcarnitine translocase; TXTP: tricarboxylate transport protein; GDC:
Grave’s disease carrier protein; ADT: ATP/ADP translocase. The ¢rst 60, 12, 21, 25, 15, and 21 aa of hMRS3/4, yMRS4, yMRS3, human
BMCP, human TXTP and human GDC, respectively, are deleted for convenience of the alignment.
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4; Pfam accession PF00153). Typical of a MCF protein with
internal targeting signals, no N-terminal targeting signal was
recognized in the polypeptide. Three mitochondrial energy
transfer protein signatures were identi¢ed in the protein (Pro-
site accession number GC0435, PDOC00189, and PS00215)
[2,3], and the protein also contained two prokaryotic mem-
brane lipoprotein attachment sites (Prosite accession number
PS00013). The N- and C-termini of the 364-aa protein were
predicted to face the mitochondrial intermembrane space. The
177-aa splice variant of hMRS3/4 was predicted to contain
three complete transmembrane domains, identical to the C-
terminus of the 364-aa protein.
3.6. Transfection of hMRS3/4 into a yeast mrs3omrs4o and
mrs2o knock-out mutants
The double knock-out mutations of yeast genes MRS3 and
MRS4 (mrs3omrs4o) caused a temperature-sensitive growth
phenotype in yeast cells, i.e. growth inhibition at 36‡C both
on fermentable (YPD) and non-fermentable (YPdG) sub-
strates, whereas growth at 28‡C was only slightly a¡ected
(Fig. 5). Single knock-out mutations (mrs3o, mrs4o) did not
show any obvious growth defect (not shown). When trans-
fected with multi-copy plasmid YEplac112-hMRS3/4, express-
ing hMRS3/4 in yeast under a constitutive promoter,
mrs3omrs4o double knock-out mutant regained growth at
36‡C both on fermentable and non-fermentable substrates,
indicating that hMRS3/4 can substitute its yeast counterparts.
Expression of the same hMRS3/4 construct from a low-copy,
centromeric plasmid (YCplac22-hMRS3/4) also restored
growth of the mrs3omrs4o mutant, although to a lesser degree
(not shown). Overexpression of yMRS3 and yMRS4 have
been reported to suppress defects in RNA splicing and cyto-
chrome biogenesis of yeast with mrs2-1 mutation, a gene in-
volved in mitochondrial Mg2 homeostasis [13,14]. When
hMRS3/4 was expressed in yeast from a multi-copy vector,
it also suppressed the growth defect of the mrs2-1 knock-out
mutant, although less e⁄ciently than yMRS3 and yMRS4
(data not shown).
3.7. Analysis of patient samples
To study the possible involvement of hMRS3/4 in the
pathogenesis of either adPEO or IOSCA, the exons, including
the splice sites, were PCR-ampli¢ed and sequenced from the
genomic DNA samples of two adPEO patients, one IOSCA
patient and two control subjects. No sequence variations be-
tween the patients and controls could be identi¢ed.
4. Discussion
We characterize here a novel human mitochondrial protein,
hMRS3/4. It is structurally and functionally homologous to
the yeast mitochondrial proteins MRS3 and MRS4, two mem-
bers of the mitochondrial carrier protein family, suggested to
translocate solutes across the inner mitochondrial membrane
[2]. MCF proteins are characterized by three repeats of about
100 aa each, with two highly conserved transmembrane helices
per repeat. The human homolog of yMRS3 and yMRS4 con-
sists of 364 aa, contains six putative transmembrane domains,
and shares structural features with mitochondrial inner mem-
brane solute carriers. The structure is typical of MCF, harbor-
ing no cleavable preproteins for mitochondrial targeting, but
possessing internal targeting information [15,16].
Single and double knock-out mutations of yMRS3 and
yMRS4 have been previously reported not to a¡ect growth
of yeast cells at 28‡C on fermentable or non-fermentable car-
bon sources [2]. We show here, however, that the mrs3omrs4o
Fig. 5. Functional complementation of the yeast mrs3omrs4o strain. Yeast S. cerevisiae strain DBY747mrs3omrs4o was transformed with vector
YEplac112-hMRS3/4 containing hMRS3/4 driven by the yeast constitutive ADH1 promoter. The transformants (mrs3omrs4o/hMRS4), untrans-
formed strain (mrs3omrs4o) and isogenic wild type strain DBY747 (MRS3MRS4) were suspended in water and 10-fold dilution series were
spotted on plates containing glycerol as non-fermentable carbon source supplemented with 0.1% glucose (YPdG) or on glucose medium (YPD).
Plates were incubated at 28 or 36‡C for 5 days. hMRS3/4 could restore the growth defect of yeast mrs3omrs4o mutants.
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double mutation in yeast causes temperature-sensitive growth
inhibition: growth at 28‡C was only slightly a¡ected, but at
36‡C it was strongly reduced on both substrates. Since single
knock-out mutations did not show a growth defect on either
temperature, the presence of either yMRS3 or yMRS4 is suf-
¢cient to sustain normal growth of yeast cells. The observed
phenotype of the double knock-out mutant is remarkable,
since most knock-out mutations in nuclear-encoded mito-
chondrial genes in yeast cause a growth defect on non-fer-
mentable substrates only. The few genes known to be essential
for growth on fermentable substrates are all involved in mi-
tochondrial protein or metabolite transport [17]. The fact that
the overexpression of yMRS3, yMRS4 and hMRS3/4 can re-
store growth and mitochondrial metal ion concentrations also
in yeast lacking the putative yeast mitochondrial Mg2 trans-
porter MRS2 ([13,14] ; Gregan and Schewyen, manuscript in
preparation) suggests a role in mitochondrial metal ion trans-
port or homeostasis. The human homolog hMRS3/4 ex-
pressed in yeast mrs3omrs4o mutant cells can substitute for
its yeast homologs and restore cell growth, which is consistent
with the conservation of the transport function from yeast to
man, and in line with observations on some other mitochon-
drial carriers [18].
hMRS3/4 is ubiquitously expressed showing the highest ex-
pression in the heart, skeletal muscle and liver. The lack of the
1.4-kb transcript on Northern hybridization analyses suggests
that we may still miss a part of the 5P untranslated region of
the gene. However, homology analyses strongly support the
start codon in the 1.4-kb cDNA to be the one suggested, and
the yeast complementation assay shows that the expressed
protein is functional. The existence of the 1.9-kb splice variant
encoding the 177-aa polypeptide is supported by numerous
EST sequences in GenBank, and the cDNA is readily ampli-
¢ed by RT-PCR in RNA extracts. The polypeptide is inter-
rupted in the middle of a conserved transmembrane region,
when compared with the structures of yMRS3 and yMRS4,
lacking 2.5 transmembrane domains of the 364-aa protein. In
spite of this, the 177-aa form is e¡ectively targeted into the
mitochondria, in which it could possibly serve a transporter
role as a dimer. The high homology of both variants to the
yeast MRS3 and 4, previously shown to be integral inner
membrane proteins of mitochondria [2], together with the
targeting of both products into the mitochondria, strongly
suggest that hMRS3/4 is a mitochondrial protein.
hMRS3/4 is located on chromosome 10q24, which also har-
bors disease gene loci for adPEO [4,5] and IOSCA [6,7]. The
tissues of adPEO patients accumulate multiple mtDNA dele-
tions, although the primary gene defect is nuclear [4]. A recent
report of mutations in the heart- and muscle-speci¢c isoform
of adenine nucleotide translocator underlying the chromo-
some 4-linked adPEO [19] made hMRS3/4 a good candidate
gene for the chromosome 10-linked disease form, since both
the proteins belong to the MCF. In addition, the mitochon-
drial expression pattern of hMRS3/4, i.e. ubiquitous expres-
sion with increased expression levels in skeletal muscle and
heart, suggested a putative role in a mitochondrial disease.
The adPEO locus overlaps with that of IOSCA [6,7], an au-
tosomal recessively inherited disease resembling closely anoth-
er recessive mitochondrial disorder, Friedreich’s ataxia (re-
viewed in [20]), and sharing a spectrum of symptoms with
PEO. We did not detect mutations in hMRS3/4 in any of
our patients, rendering it unlikely as the disease gene under-
lying these disorders.
The high homology of hMRS3/4 with other MCF members,
as well as the common signature sequences, its mitochondrial
location and the ability to replace the functions of the homol-
ogous yeast proteins, strongly support that it belongs to the
MCF and shares the role of its yeast counterparts in human
cells i.e. the transport of ions across the inner mitochondrial
membrane. Its essential role for growth in yeast cells and
conservation across species indicate that the MRS proteins
are important for eukaryotes. Further studies on the function
of hMRS3/4 may provide new insights in the functions of
these MCF proteins in general.
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